Replies to post #147518 on Biotech Values

[iandy]

I don't think it is "dumb" to be skeptical when evaluating incomplete data.
Especially from a company that has pumped incomplete data previously.

http://www.fiercebiotech.com/tags/bavituximab

[masterlongevity]

I don't know jackshit about PPHM, but I do trust quite a few people on this board.

I also know Rob Garnick personally from Genentech. He was great at his position, but in the last 10 yrs, mostly a beauracrat leading a very large regulatory group, meaning he didn't actually develop reg strategies (and certainly not clin dev plans) and didn't meet with FDA/EMA; but he did approve new hires, hi level reg plans, etc. He was there for 17 approvals, and may officially had "oversight", but the devils in the details.


My point to you about negative data at conferences has nothing to do with PPHM. Itis a very common mistake, in general,(made by people who have no idea what they are talking about) that only positive data would be presented at plenary sessions. Negative data are presented all the time.
So if someone who is uneducated enough to assume a drug works based on it being presented at a conference, should probably not be investing in biotech.